CompletedNot Applicable

Risk of Developing Antibodies to Heparin-PF4 After Heart Surgery

United States1,015 participantsStarted 2006-06

Plain-language summary

Heparin is a drug that is widely used to prevent and treat blood clotting. Individuals undergoing cardiopulmonary bypass surgery are administered high doses of heparin, and some of them develop antibodies to the drug. This immune response can lead to the formation of blood clots, setting the stage for a potential heart attack or stroke. The purpose of this study is to evaluate how often an immune response to heparin leads to the formation of blood clots in individuals who have had heart surgery.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Scheduled for cardiac bypass surgery at Duke University Hospital Exclusion Criteria: * Plans to receive warfarin during the post-operative inpatient stay * Plans to receive a full anticoagulant dose of low-molecular weight heparin during the post-operative inpatient stay * Plans to receive a full anticoagulant dose of unfractionated heparin during the post-operative inpatient stay * Use of any drug other than unfractionated heparin for anticoagulation during cardiopulmonary bypass * Warfarin, heparin, or low-molecular weight heparin administered during a readmission to the hospital for a reason other than one of this study's outcomes does not constitute criteria for exclusion

What they're measuring

Thrombotic events compatible with HIT

Timeframe: one year

Trial details

NCT IDNCT00237328

SponsorDuke University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2009-03

View on ClinicalTrials.gov More Thrombosis trials